Trials / Completed
CompletedNCT01299077
Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China
A Retrospective Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar Disc Degenerative Disease in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 478 (actual)
- Sponsor
- Eisai China Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe the overall satisfaction of patients with degenerative disc disease after receiving triple therapy.
Detailed description
DDD (lumbar disc degenerative disease ) patients who have been prescribed triple therapy (MBL+ MYO+ NSAIDs) over 2 weeks of triple therapy were enrolled in the study. They were asked to assess their overall satisfaction degree on triple therapy.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-09-01
- Completion
- 2010-11-01
- First posted
- 2011-02-18
- Last updated
- 2011-12-28
- Results posted
- 2011-11-28
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01299077. Inclusion in this directory is not an endorsement.